Every 424B that Kazia Therapeuti (KZIA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow KZIA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KZIA filings page.
Kazia Therapeutics Limited filed a prospectus supplement covering 274,666 American Depositary Shares, each representing ordinary shares, and uses it to attach and highlight a new Form 6-K disclosure.
The company reports it failed to regain compliance with Nasdaq’s Market Value of Listed Securities requirement, which mandates at least $35 million in market value under Nasdaq Listing Rule 5550(b)(2) by the November 10, 2025 compliance date. On November 12, 2025, Nasdaq staff issued a determination letter stating that Kazia had not met this requirement and that its securities are subject to suspension and potential delisting.
Kazia plans to timely request a hearing before a Nasdaq Hearings Panel, which will automatically stay any suspension or delisting action while the hearing process and any Panel-granted extension period are pending. The company states it intends to demonstrate its ability to regain and sustain compliance, but cautions there is no assurance the Panel will accept its plan or that it will ultimately meet the listing standards.